Dechra Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 2/6

Dechra Pharmaceuticals verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 14%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 6.2%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 12.5%. Die Eigenkapitalrendite von Dechra Pharmaceuticals beträgt 4.8% und die Nettomargen betragen 5.5%.

Wichtige Informationen

14.0%

Wachstumsrate der Gewinne

11.0%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	12.4%
Wachstumsrate der Einnahmen	12.5%
Eigenkapitalrendite	4.8%
Netto-Marge	5.5%
Nächste Ertragsaktualisierung	04 Sep 2023

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie Dechra Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

BMV:DPH N Einnahmen, Ausgaben und Erträge (GBP Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Dec 22	727	40	280	49
30 Sep 22	704	49	267	43
30 Jun 22	682	58	253	36
31 Mar 22	661	66	239	35
31 Dec 21	641	73	225	35
30 Sep 21	624	64	224	36
30 Jun 21	608	56	222	37
31 Mar 21	587	50	215	36
31 Dec 20	566	44	208	35
30 Sep 20	541	39	203	35
30 Jun 20	515	34	199	34
31 Mar 20	507	31	200	34
31 Dec 19	499	29	201	33
30 Sep 19	490	30	198	32
30 Jun 19	482	31	196	32
31 Mar 19	463	28	191	31
31 Dec 18	444	25	186	29
30 Sep 18	426	30	171	28
30 Jun 18	407	36	156	26
31 Mar 18	394	40	147	26
31 Dec 17	381	43	137	26
30 Sep 17	370	35	133	26
30 Jun 17	359	26	129	26
31 Mar 17	334	19	122	23
31 Dec 16	309	11	115	19
30 Sep 16	278	12	105	15
30 Jun 16	248	13	95	10

Qualität der Erträge: DPH N hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: DPH NDie aktuellen Gewinnspannen (5.5%) sind niedriger als im letzten Jahr (11.4%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: DPH NIn den letzten 5 Jahren sind die Gewinne von 14% jährlich gestiegen.

Beschleunigtes Wachstum: DPH NDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.

Erträge im Vergleich zur Industrie: DPH N hatte im vergangenen Jahr ein negatives Gewinnwachstum (-45%), was einen Vergleich mit dem Branchendurchschnitt Pharmaceuticals (8.5%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: DPH NDie Eigenkapitalrendite des Unternehmens (4.8%) wird als niedrig angesehen.

Dechra Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Less than half of directors are independent

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Less than half of directors are independent

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Announces Executive Changes

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Non-Executive Chairman recently bought Mex$2.6m worth of stock

Investor sentiment improved over the past week

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Investor sentiment deteriorated over the past week

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Less than half of directors are independent

Upcoming dividend of UK£0.29 per share

Less than half of directors are independent

Non-Executive Director recently bought Mex$178k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Less than half of directors are independent

Board Member recently sold Mex$27m worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

CEO, MD & Executive Director recently sold Mex$279m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Non-Executive Director recently bought Mex$712k worth of stock

Independent Non Executive Director recently sold Mex$3.5m worth of stock

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren